US FDA Approves Opdivo^® (Nivolumab) Plus Yervoy^® (Ipilimumab) As a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

Bristol Myers Squibb announced that the US FDA approved Opdivo®plus Yervoy® as a first-line treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.